Reports that the Food and Drug Administration (FDA) has authorized availability of copolymer-1 injection for treatment use in patients with exacerbating-remitting multiple sclerosis. Use of the drug under a Treatment Investigational New Drug (IND) protocol; Details of certain restrictions.